anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
<P>PROBLEM TO BE SOLVED: To provide an imaging control apparatus for a medical image for advancing imaging rapidly by simplifying operation input before imaging without applying load to a patient.  <P>SOLUTION: A control part 11 applies an order number at every reserved imaging in imaging control processing and determines an imaging order so that imaging by a same reader continues on the basis of the reservation data acquired from a reservation device 2 and the designation input due to a radiotherapist to store the data related to reservation and the imaging order in an imaging order control table. Subsequently, imaging is carried out on the basis of the stored imaging order and an imaging image confirmation screen on a display part 13. An imaging condition button is displayed on the imaging image confirmation screen and a cursor is moved to the imaging condition button during imaging to set a selection state. Further, medical image data is displayed on the selected data display region after imaging and, when the push-down signal of an OK button is acquired from an input part, imaging is completed to be transferred to the next imaging and the cursor is moved to the imaging condition button of the next imaging.  <P>COPYRIGHT: (C)2004,JPO
Patients receive oral tretinoin twice daily on days 1-7, oral mercaptopurine once daily on days 1-14, and oral methotrexate on day 1. Treatment repeats every 2 weeks for up to 1 year.
OBJECTIVES: I. Determine the toxic effects and maximum tolerated dose (MTD) of LY231514 in patients with metastatic or locally advanced solid tumors and varying degrees of renal function. II. Determine the recommended dose for LY231514 in this patient population. III. Examine the effects of renal dysfunction on the pharmacokinetics of LY231514 in this patient population. IV. Examine the relationship between impaired renal function, drug exposure, and drug effects in these patients. V. Gather data for development of a LY231514 dosing nomogram based on renal function. VI. Collect preliminary data regarding antitumor effects of LY231514 in this patient population.

OUTLINE: This is an open label, dose escalation study. Patients are stratified according to renal function. Group 1 consists of patients with normal renal function, and groups 2, 3, and 4 consist of patients with mild, moderate, and severe renal impairment. All patients receive LY231514 IV over 10 minutes every 3 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients are treated with escalating doses of LY231514 within each treatment group. If dose limiting toxicity (DLT) is observed in 1 of 3 patients at a given dose level, then 3 additional patients are studied. The maximum tolerated dose is defined as the dose level at which less than 2 of 6 patients experience DLT. Patients are followed until death.

PROJECTED ACCRUAL: Up to 50 patients will be accrued for this study.
The invention discloses a preparation method of traditional Chinese medicinal semen cassiae mimosoidis solution for treating constipation. The traditional Chinese medicinal semen cassiae mimosoidis solution is prepared from the following raw materials in parts by weight: 7-25 parts of dry semen cassiae mimosoidis, 10-50 parts of radix astragali, 5-25 parts of radix salviae miltiorrhizae, 5-16 parts of flaxseeds, 10-30 parts of radix rehmanniae preparata, 3-14 parts of fructus crataegi, 60-90 parts of stems and leaves of crowndaisy chrysanthemum, 15-30 parts of roots of Ficus beecheyana Hook. et Arn., 6-10 parts of peach kernels, and 6-25 parts of red koji. The ethanol concentration for extracting the traditional Chinese medicinal semen cassiae mimosoidis solution is 5%-30% (volume ratio) and the extracting time is 5-30 days. The preparation method of the traditional Chinese medicinal fructus cannabis solution for treating constipation is safe, non-toxic and pollution-free, and is low in cost. The solution containing alpha-linolenic acid is used for washing garbage (toxins) in blood and blood vessels, and the solutions of fructus crataegi, medicated leaven and the like are adopted for promoting the sufficient digestive absorption of the intestines and stomach for nutrition, so that the nutrition (energy) demand of metabolism (such as blood nourishing) and physiological activity of the body can be satisfied. The medicines for washing the blood and supplementing the nutrition (energy) as well as treating constipation assist the immune system with the medicine function, so that the constipation due to intestinal dryness is converted into the relaxed bowl. In addition, the traditional Chinese medicinal semen cassiae mimosoidis solution also can resist disease attack, and enables some diseases of the body to be self-cured.
In G-CSF treatment group, all participants are treated with G-CSF at the dose of 5ug/kg per day until neutrophil higher than 0.5 g/L or 14 days from day three after induction therapy. MRD is monitored at day 14 and 28 with flow cytometry and quantity PCR if a fusion gene is available.
Parkinson's disease(PD) lacks a biomarker for disease progression. To analyze how cerebrospinal fluid (CSF), glucosylceramide (GlcCer), sphingomyelin (SM), or serum neurofilament light chain (NfL) associate with progression of PD in a retrospective cohort, we used linear mixed-model regressions between baseline biomarkers and change in dopamine transporter brain-imaging (DaTscan©), Montreal cognitive assesment (MoCA), or global composite outcome (GCO) score. In 191 PD patients, biomarkers were not associated with DaTscan or MoCA change over 2.1 years. Higher baseline GlcCer/SM ratio and serum-NfL nonsignificantly associated with increase in GCO score. Results do not support a role for CSF-sphingolipid/serum-NfL to predict cognitive and DaTscan progression in early-PD. Potential prediction of global clinical change warrants further study.
INTRODUCTION: Poststroke complex regional pain syndrome (CRPS) is an important complication in stroke survivors. The identification of factors associated with post-stroke CRPS is important for preventive measures and early diagnosis.
METHODS: A total of 141 first-ever stroke survivors in the subacute stage were retrospectively analyzed. Demographic data, diagnosis time, duration of hospitalization, location of brain lesion, etiology, comorbidities, and blood test findings were investigated. Clinical data included Medical Research Council (MRC) grade, Fugl-Meyer assessment (FMA), National Institute for Health Stroke Scale (NIHSS), Berg Balance Scale (BBS).
RESULTS: Among 141 patients with subacute stroke, 22 were diagnosed with CRPS, with a prevalence of 15.6 %. The mean time to diagnosis was 38.6 (±16.5) days. The prevalence according to the degree of paralysis was 33.3 % in MRC grades 0 and 1, 8.6 % in grade 2, and 0 % in grade 3 or higher. The incidence rates within 1 month after stroke were 1.42 % and 22.47 % between 1 and 3 months after stroke, respectively. The independent risk factors for CRPS were hospitalization duration and FMA, NIHSS, and BBS scores. The sensitivity and specificity of the NIHSS score for predicting post-stroke CRPS were 86.4 % and 59.7 %, respectively, with an optimal cutoff value of 7.5.
CONCLUSIONS: CRPS of the affected upper limb in stroke patients is associated with stroke severity, including paralysis, and the incidence increases over time during the subacute phase. Additionally, having sufficient strength to move through a full range of motion against gravity had a protective effect against CRPS.
INVERSINE1 should not be used in mild, moderate, labile hypertension and may prove unsuitable in uncooperative patients. It is contraindicated in coronary insufficiency or recent myocardial infarction.

INVERSINE1 should be given with great discretion, if at all, when renal insufficiency is manifested by a rising or elevated BUN. The drug is contraindicated in uremia. Patients receiving antibiotics and sulfonamides should generally not be treated with ganglion blockers. Other contraindications are glaucoma, organic pyloric stenosis or hypersensitivity to the product.
Cisplatin, a platinum-containing alkylating agent, is used in the treatment of various tumors owing to its potent antitumor activity. However, it causes permanent and adverse effects, particularly hearing loss and depletion of ovarian reserve. Until recently, there were no clinically available protective agents to mitigate the adverse side effects of cisplatin-induced cytotoxicity. In 2022, sodium thiosulfate (STS) was approved by the Food and Drug Administration for mitigating hearing loss in children and adolescents undergoing cisplatin treatment. Consequently, our investigation aimed to determine if STS could protect ovarian reserve against cisplatin-induced gonadotoxicity. In an ex vivo culture, the cisplatin-only group exhibited a loss of primordial follicles, while post-STS administration after cisplatin exposure effectively protected primordial follicles. However, when post-STS was administrated either 6 or 4 h after cisplatin exposure, it did not confer protection against cisplatin-induced gonadotoxicity in postnatal day 7 or adolescent mouse models. Immunofluorescence assays using γH2AX and cPARP revealed that oocytes within primordial follicles exhibited DNA damage after cisplatin exposure, irrespective of post-STS administration. This underscores the rapid and heightened sensitivity of oocytes to gonadotoxicity. In addition, oocytes demonstrated an increased expression of pCHK2 rather than pERK, suggesting that the pathway leading to oocyte death differs from the pathway observed in the inner ear cell death following cisplatin exposure. These results imply that while the administration of STS after cisplatin is highly beneficial in preventing hearing loss, it does not confer a protective effect on the ovaries in mouse models.
INTRODUCTION: Obesity prevalence in Military Health System (MHS) children has been reported through fiscal year (FY) 2012 as consistently lower than in the general population. Our study reports military pediatric overweight, obesity, and severe obesity prevalence through FY2018. We compared FY2018 prevalence to a sample of the general population using National Health and National Health and Nutrition Examination Survey (NHANES) 2017-2018 data.
MATERIALS AND METHODS: The MHS Data Repository was queried for all children aged 2-17 years seen at any military treatment facility between FY2012 and FY2018. We calculated overweight and obesity (classes 1, 2, and 3) prevalence for each FY and performed subgroup analysis for sex, age, and sponsor rank. We also compared FY2018 to NHANES 2017-2018 data. This study was approved by the Walter Reed National Military Medical Center Institutional Review Board.
RESULTS: The prevalence of overweight and obesity was stable from FY2012 (14.4% and 11.3%, respectively) to FY2018 (14.1% and 10.7%). Rates of classes 2 and 3 obesity combined were also stable at around 2.5% of all children. In FY2018, obesity prevalence was greater in assigned males, increased with age, and was highest in 16-17-year-olds (odds ratio: 2.75) and children with an enlisted military sponsor (odds ratio: 1.78). Compared to NHANES, MHS children had lower rates of obesity (10.7% versus 19.3%) with a smaller proportion of severe obesity (24% versus 32%).
CONCLUSIONS: The prevalence of pediatric overweight and obesity in the MHS was stable over time. Disparities were observed between age and sponsor rank groups. When compared to the general population, overall obesity prevalence was lower in younger military children. Further research is needed to explore disparities and to identify optimal strategies to mitigate the increase in obesity prevalence with age.
After enrollment, the patients in treatment group were orally administered with a starting dose of 80mg qd for 21 days. On the 21st day of the 4th cycle, if the patient has no tumor progression and no intolerable toxicity, after the researcher determines that the drug therapy can be continued, the patient should take linperlisib 80mg qd for two consecutive weeks per cycle and stop taking it for one week, and conduct regular safety and tumor efficacy evaluation until the disease progresses, toxicity becomes intolerable or the researcher determines that it is not suitable to continue treatment. The maximum duration of treatment is two years.
The invention relates to medical information systems, medical devices, methods, and non-transitory computer readable media. A communication control unit of an external communication device requests a communication connection with a server. When a communication connection is established with the server, the communication control unit acquires a server-side definition file from the server. An updating unit of the external communication device updates the client-side definition file using the server-side definition file acquired by the communication control unit. The communication control unit of the external communication device is configured to upload the medical device-side data to the server based on the client-side definition file. In addition, the communication control unit of the external communication device is configured to reject the connection request from the server.
A hyperspectral facial analysis system and method for personalized health scoring to assess the risk that a person has a disease. Embodiments capture images in multiple spectral bands, such as visible, infrared, and ultraviolet, and analyze these images to generate multiple health metrics, such as pallor, temperature, sweat, and chromophores. These metrics may be combined into an overall health score that may be used for screening. Image analysis may focus on the area under the eyes, where skin is thinnest. Images may be compared to a reference population to identify anomalous values, so that health scoring automatically adjusts for local conditions. Pallor may be calculated based on hue and saturation of visible light images. Temperature may be calculated based on infrared image intensity. Sweat may be calculated using cross-polarized images to identify specular highlights. Chromophores may be calculated by comparing frequency domain ultraviolet images to those of the reference population.
The aim of the study is to evaluate the performances and prognostic impact of coronary angiography \& IVUS-based algorithms for decision making and stent optimization in a multicenter, prospective cohort. Between January 2020 and June 2025, a total of 3,000 patients who performed coronary angiography (± FFR) and have at least one coronary stenosis requiring PCI (as culprit) will be enrolled from 15 centers in South Korea. In addition, the deferred lesions with visual estimated diameter stenosis of \>30% will be evaluated as non-culprits. Brief study design is as depicted in the following figure.

Supervised ML algorithms include: 1) angiography- and IVUS-based algorithms for predicting FFR, 2) IVUS-based algorithm for plaque characterization, 3) IVUS-based algorithm for predicting stent expansion, and 4) post-stenting IVUS-based algorithm for predicting stent failure. In the prospective cohort, the performance of each model will be assessed. This registry trial composed of the treated (culprit) and the deferred (nonculprit) coronary lesions has two primary objectives as follow; 1) Primary objectives in treated (culprit) lesions is to see the impact of the integrated ML model on the development of culprit-related 2-year target vessel failure (TVF). 2) Primary objectives in deferred (nonculprit) lesions is to see the impact of the integrated ML model on the development of nonculprit-related 2-year TVF.
Chronic periodontitis is a chronic, progressive, and destructive disease. Especially, the large accumulation of advanced glycation end products (AGEs) in a diseased body will aggravate the periodontal tissue damage, and AGEs induce M1 macrophages. In this project, the novel nanodrugs, glucose-PEG-PLGA@MCC950 (GLU@MCC), are designed to achieve active targeting with the help of glucose transporter 1 (GLUT1) which is highly expressed in M1 macrophages induced by AGEs. Then, the nanodrugs release MCC950, which is a kind of NLRP3 inhibitor. These nanodrugs not only can improve the water solubility of MCC950 but also exhibit superior characteristics, such as small size, stability, innocuity, etc. In vivo experiments showed that GLU@MCC could reduce periodontal tissue damage and inhibit cell apoptosis in periodontitis model mice. In vitro experiments verified that its mechanism of action might be closely related to the inhibition of the NLRP3 inflammatory factor in M1 macrophages. GLU@MCC could effectively reduce the damage to H400 cells caused by AGEs, decrease the expression of NLRP3, and also obviously reduce the M1-type macrophage pro-inflammatory factors such as IL-18, IL-1β, caspase-1, and TNF-α. Meanwhile, the expression of anti-inflammatory factor Arg-1 in the M2 macrophage was increased. In brief, GLU@MCC would inhibit the expression of inflammatory factor NLRP3 and exert antiperiodontal tissue damage in chronic periodontitis via GLUT1 in the M1 macrophage as the gating target. This study provides a novel nanodrug for chronic periodontitis treatment.
Described herein is a method of modulating sumoylation of a Ras protein by small ubiquitin-like modifier (SUMO) proteins. Provided herein is a method for regulating the activity of a Ras protein. Also provided is a treatment of proliferative diseases, such as cancer, by introducing specific mutations to a mutant Ras protein that is associated with the proliferative disease. Described herein is a modified Ras protein. Described herein are recombinant vectors, cells comprising the vectors expressing the modified Ras proteins. Provided herein is an antibody that specifically binds to a sumoylated Ras protein. Described herein is a method for identifying an agent that interferes with the sumoylation of a Ras protein. Also described herein are therapeutic and prophylactic compositions. Also provided herein is a method of using a modified Ras protein to replace an endogenous mutant Ras protein that is associated with a proliferative disease.
All patients will be invited to complete the McGill Quality of Life Questionnaire - Revised (McGill QOL-R) upon admission to the unit. The Questionnaire will not be part of the permanent medical record and the participants will remain anonymous. Afterwards participants will be asked if they would like to listen to music during their stay in the hospital. Music will be selected according to their choices from an i-Tunes playlist. Participants will be invited to listen to music at their own discretion. Prior to discharge from the hospital or after 3 days all willing participants will be again invited to complete the McGill QOL-R questionnaire.
Freezing of gait (FoG) is one of the most distressing symptoms of Parkinson's Disease (PD), commonly occurring in patients at middle and late stages of the disease. Automatic and accurate FoG detection and prediction have emerged as a promising tool for long-term monitoring of PD and implementation of gait assistance systems. This paper reviews the recent development of FoG detection and prediction using wearable sensors, with attention on identifying knowledge gaps that need to be filled in future research. This review searched the PubMed and Web of Science databases to collect studies that detect or predict FoG with wearable sensors. After screening, 89 of 270 articles were included. The data description, extracted features, detection/prediction methods, and classification performance were extracted from the articles. As the number of papers of this area is increasing, the performance has been steadily improved. However, small datasets and inconsistent evaluation processes still hinder the application of FoG detection and prediction with wearable sensors in clinical practice.
Lung-protective ventilation strategies are recommended for patients under mechanical ventilation with intermediate-risk and high-risk in order to minimize lung injury and respiratory complications of critically ill patients associated with mechanical ventilation , such as atelectasis and pneumonia. Low tidal volume (TV) had been proven protective . However, there is no consensus on what the optimal positive end expiatory pressure (PEEP) is for patients with healthy lungs undergoing general anesthesia, particularly for those who are undergoing abdominal surgery. A recent study showed that electrical impedance tomography (EIT) could be used to identify optimal PEEP, where both lungs collapse, hyper-insufflation is minimized, and the variation of optimal PEEP in patients with healthy lungs undergoing abdominal surgery is profound.Therefore, a fixed PEEP applied to all patients surely over-PEEP some and under-PEEP others. This study also demonstrates that maintaining the optimal PEEP intra-operatively not only improves intra-operative oxygenation but also reduces the incidence and severity of atelectasis post-operatively . Even though this study focuses on the improvement of physiology rather than the outcome, the benefit of intra-operative optimal PEEP is sustained for at least for one-hour post extubation. Therefore, optimized intra-operative PEEP could potentially have a positive impact onoutcomes. However, the cost-effectiveness of EIT used intraoperatively as routine practice still needs to be determined. Development of new methods which can be used intraoperatively and arecost-effective and user-friendly is an unmet demand.

Recently, Ferrando et al conducted a study in which the authors used minimal FiO2 to maintain clinically acceptable arterial blood O2 saturation by titrating PEEP. Even though this study was not randomized and sample size was insufficient to demonstrate improved outcomes, it clearly demonstrated its feasibility and safety. We hypothesize that titration of intraoperative PEEP using minimal FiO2 while maintaining clinically acceptable O2 saturation allows clinicians to identify the optimal PEEP. We will test this hypothesis on patients undegoing RALP. We chose this population because these patients have increased number of postoperative complications . Additionally, physicians are prone to using suboptimal ventilation strategies such as inappropriate tidal volumes and intraoperative PEEP in this population; therefore these patients are more likely to achieve maximal benefit with optimized intra-operative PEEP.
The invention relates to a cosmetic and the preparation technology of the cosmetic. The cosmetic is used for preventing wrinkles, whitening and removing acne and scar. At present, a lot of medicines are available for preventing wrinkle, whitening and removing the acne and the scar. As most of the medicines are Chinese medicinal herb, sufferers feel annoyed about long treatment period and poor curative effects. In the invention, 79.89g of refined sesame oil mixed with blend oil is heated to 80 DEG C. After 0.02g of tween-80 is added into the refined sesame oil, the refined sesame oil is stirred to be dissolved. After being heated to 100 DEG C, 10g of white petroleum jelly, 0.02g of ethyl hydroxyl benzoate, 10g of snake oil and 0.02g of zinc acetate are added into the refined sesame oil in sequence. The refined sesame oil is stirred for 30 minutes while being kept warm. The refined sesame oil is stirred until the white petroleum jelly, the ethyl hydroxyl benzoate, the snake oil and the zinc acetate are scattered evenly and cooled to below 30 DEG C. Afterwards, borneol is added into the refined sesame oil and stirred for 10 minutes. The cosmetic can be used for preventing wrinkles, whitening, removing the acne and spot, exfoliating scrub, refining pores, removing the scar, treating sun burn, brush burn, skin injury, scrotitis burn and frostbite, freeze prevention, cracking resistance, aging resistance and repairing damaged skin. The cosmetic has low manufacturing cost and no adverse effects. Therefore, the invention is safe and reliable and is easy to be popularized.